Developing and experimentally validating a glucocorticoid signaling-related gene signature to evaluate the prognosis and immunotherapeutic response in kidney renal clear cell carcinoma
PLOS One · 2025
DOI: 10.1371/journal.pone.0334104 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Yu Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Glucocorticoids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Science and Technology Program of Guangzhou, Shenzhen Third People’s Hospital Research Fund.
Abstract (Originalsprache)
Glucocorticoids play a pivotal role in tumorigenesis and cancer progression. However, the prognostic significance of glucocorticoid signaling-related genes remains poorly understood, particularly in kidney renal clear cell carcinoma (KIRC). Collected samples indicated KIRC patients exhibited elevated serum glucocorticoid levels compared to healthy donors ( P < 0.05). Glucocorticoid signaling-related genes were curated from the MSigDB database. The TCGA-KIRC cohort was utilized for training, while 7 independent public KIRC cohorts and local samples were employed for validation. Through LASSO and random forest analyses, ACADM, ANGPTL4, and NFKB2 were identified and subsequently incorporated into a multivariate Cox regression model. This gene signature emerged as a robust prognostic indicator across multiple cohorts (pooled hazard ratio [HR] = 2.73, 95% confidence interval [CI] = 2.05–3.65). In local samples, KIRC tissues exhibited increased infiltration of NFKB2+ cells and decreased levels of ACADM+ and ANGPTL4+ cells (all P < 0.05). Meta-analyses and spatial transcriptomics revealed a positive association between the signature and CD8+ T cell infiltration. Furthermore, the signature was associated with T cell exhaustion levels and could predict immunotherapeutic responses in both computational simulations and real-world clinical settings (all P < 0.05). In vivo experiments showed that NFKB2 knockdown inhibited tumor growth and the expansion of CD8+PDCD1+ T cells, effects that were reversible with corticosterone treatment (all P < 0.05). Collectively, a glucocorticoid signaling-related gene signature was developed and rigorously validated as a predictive tool for prognosis and immunotherapeutic response in KIRC, offering valuable insights for guiding personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Urology, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
- Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Wei Luo, Wanlong Tan
Förderung
- The Science and Technology Program of Guangzhou
- Shenzhen Third People’s Hospital Research Fund
Zitieren
APA
Zhang, Y., Chen, C., Zhu, T., Luo, W., Zhou, R., & Tan, W. (2025). Developing and experimentally validating a glucocorticoid signaling-related gene signature to evaluate the prognosis and immunotherapeutic response in kidney renal clear cell carcinoma. PLOS One. https://doi.org/10.1371/journal.pone.0334104
Vancouver
Zhang Y, Chen C, Zhu T, Luo W, Zhou R, Tan W. Developing and experimentally validating a glucocorticoid signaling-related gene signature to evaluate the prognosis and immunotherapeutic response in kidney renal clear cell carcinoma. PLOS One. 2025. doi:10.1371/journal.pone.0334104
BibTeX
@article{Zhang2025,
author = {Zhang, Yu and Chen, Chen and Zhu, Tianhang and Luo, Wei and Zhou, Ranran and Tan, Wanlong},
title = {Developing and experimentally validating a glucocorticoid signaling-related gene signature to evaluate the prognosis and immunotherapeutic response in kidney renal clear cell carcinoma},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0334104}
}
EUVIMED